Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $138.0 million.

  • Phathom Pharmaceuticals' Cash & Equivalents fell 59.11% to $138.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.0 million, marking a year-over-year decrease of 59.11%. This contributed to the annual value of $300.1 million for FY2024, which is 21.89% down from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Cash & Equivalents is $138.0 million, which was down 9.46% from $152.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Cash & Equivalents ranged from a high of $384.3 million in Q4 2023 and a low of $130.1 million during Q1 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $249.4 million (2023), whereas its average is $248.0 million.
  • In the last 5 years, Phathom Pharmaceuticals' Cash & Equivalents skyrocketed by 149.92% in 2024 and then plummeted by 59.11% in 2025.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Cash & Equivalents stood at $155.9 million in 2022, then soared by 146.49% to $384.3 million in 2023, then fell by 21.89% to $300.1 million in 2024, then tumbled by 59.11% to $138.0 million in 2025.
  • Its Cash & Equivalents was $138.0 million in Q3 2025, compared to $152.4 million in Q2 2025 and $215.2 million in Q1 2025.